Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.
about
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignAn alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmissionNaturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralizationClearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responsesA weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infectionNaturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.Neutralizing antibodies to hepatitis C virus in perinatally infected children followed up prospectivelyBreadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.Antigenic cooperation among intrahost HCV variants organized into a complex network of cross-immunoreactivity.Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, ChallengeBroad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV InfectionB-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins.The role of humoral innate immunity in hepatitis C virus infection.Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies.Pseudotypes: your flexible friends.The past, present and future of neutralizing antibodies for hepatitis C virus.Divergent quasispecies evolution in de novo hepatitis C virus infection associated with bone marrow transplantation.A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.T-bet-expressing B cells during HIV and HCV infections.Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.Flexible and rapid construction of viral chimeras applied to hepatitis C virus.Patterns of longitudinal change in hepatitis C virus neutralization titers correlate with the outcome of peginterferon and ribavirin combination therapy.Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.Immunopathogenesis of Hepatitis C Virus Infection.Defining Breadth of Hepatitis C Virus Neutralization
P2860
Q26801759-3A9D52CB-E3B9-4F87-9C18-6A9538FC2AA2Q27684354-96CFB515-B24B-4F3D-B2DD-3B4EA399FE36Q28731355-5DCF48FA-F034-4A2B-B9BA-A12C2F54638AQ33707246-7205C758-9ED6-4201-89F0-34BE4BE2E2A3Q34009510-756BC970-17E7-4CBF-8AD7-1BE855B60F9FQ35242585-EE519B6A-1120-4E56-B678-56630EF409FEQ35557115-D7E51F2D-9368-4FF0-A654-B3B51A5D1210Q35557994-227DF910-1DDB-451B-8620-047024BA9AFAQ35669397-3F332BDE-F1C9-48B8-BF7A-C1BE1853CC91Q35913863-C344FF94-7043-4234-A254-28950C57C572Q36811958-FED2ECEB-8B97-49A6-B9E7-2A34EE6D1795Q37623529-AFF675C2-19F4-439A-B3CA-F020B8D16E15Q37987129-5C10E46D-679C-459F-965C-6ABBC12A5DDFQ38128299-EC8B2609-AFA4-4C6D-A172-37ED41BE46E2Q38191236-B8299385-805F-4CC7-96B7-BC1E6CE600DEQ38192357-0F4B79B6-E7CB-496B-AF8F-57539BD0B92AQ38741285-B04CBA37-A1A4-4FAB-B8D9-4C3367327D5EQ38809451-27236BA1-EA17-4730-8F19-A9B9EAF3234CQ39454938-5484A5B0-2453-4735-A00E-541B91C76539Q40634075-90F3FFF5-0870-4BE6-A401-08FD526CAB63Q40688888-E73DCE9B-1E78-462F-94D1-4A2C828B755DQ41503166-41232E48-9BF3-4173-BF1D-2CD949714606Q41619358-EA9339B8-B0B9-4FA9-A390-C92DCA1E7322Q45325612-D24A8239-F90A-4E6D-AF47-C6F2A5210483Q50934385-A0140D9B-7B83-4BBC-8ADF-42773D749004Q56395915-797BA63B-8CEF-470B-B0ED-3D44C6D96CC1
P2860
Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralization serotype.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Hepatitis C patient-derived gl ...... t not neutralization serotype.
@ast
Hepatitis C patient-derived gl ...... t not neutralization serotype.
@en
type
label
Hepatitis C patient-derived gl ...... t not neutralization serotype.
@ast
Hepatitis C patient-derived gl ...... t not neutralization serotype.
@en
prefLabel
Hepatitis C patient-derived gl ...... t not neutralization serotype.
@ast
Hepatitis C patient-derived gl ...... t not neutralization serotype.
@en
P2093
P2860
P50
P356
P1433
P1476
Hepatitis C patient-derived gl ...... ut not neutralization serotype
@en
P2093
Anna Albecka
C Patrick McClure
Mohamed R Hamed
P2860
P304
P356
10.1128/JVI.01332-10
P407
P577
2011-02-16T00:00:00Z